Higher anti-depressant dose and major adverse outcomes in moderate chronic kidney disease: a retrospective population-based study by Varun Dev et al.
Dev et al. BMC Nephrology 2014, 15:79
http://www.biomedcentral.com/1471-2369/15/79RESEARCH ARTICLE Open AccessHigher anti-depressant dose and major adverse
outcomes in moderate chronic kidney disease:
a retrospective population-based study
Varun Dev1, Stephanie N Dixon1,2,3,4, Jamie L Fleet2, Sonja Gandhi1,2,3, Tara Gomes4,5,6, Ziv Harel7, Arsh K Jain1,2,3,
Salimah Z Shariff1,4, Davy Tawadrous1,2, Matthew A Weir1,2,3 and Amit X Garg1,2,3,4,8*Abstract
Background: Many older patients have chronic kidney disease (CKD), and a lower dose of anti-depressants paroxetine,
mirtazapine and venlafaxine is recommended in patients with CKD to prevent drug accumulation from reduced
elimination. Using information available in large population-based healthcare administrative databases, we conducted
this study to determine if ignoring the recommendation and prescribing a higher versus lower dose of anti-depressants
associates with a higher risk of adverse events.
Methods: We conducted a population-based cohort study to describe the 30-day risk of delirium in older adults who
initiated a higher vs. lower dose of these three anti-depressants in routine care. We defined delirium using the best
proxy available in our data sources - hospitalization with an urgent head computed tomography (CT) scan. We
determined if CKD status modified the association between anti-depressant dose and outcome, and examined the
secondary outcome of 30 day all-cause mortality. We used multivariable logistic regression analyses to estimate
adjusted odds ratios (relative risk (RR)) and 95% confidence intervals.
Results: We identified adults (mean age 75) in Ontario who started a new study anti-depressant at a higher dose
(n = 36,651; 31%) or lower dose (n = 81,160; 69%). Initiating a higher vs. lower dose was not associated with an
increased risk of hospitalization with head CT (1.09% vs. 1.27% (adjusted RR 0.90; 95% CI, 0.80 to 1.02), but was associated
with a lower risk of all-cause mortality (0.76% vs. 0.97% RR 0.82; 95% CI, 0.71 to 0.95). Neither of these relative risks were
modified by the presence of CKD (p = 0.16, 0.68, respectively).
Conclusions: We did not observe an increase in two adverse outcomes when study anti-depressants were initiated
at a higher dose in elderly patients with moderate CKD. Contrary to our hypothesis, the 30-day risk of mortality was
lower when a higher versus lower dose of anti-depressant was initiated in these patients, a finding which requires
corroboration and further study.
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Anti-depressants are among the most widely prescribed
medications worldwide and depression is the most com-
mon mental health problem in the elderly [1-5]. The
prevalence of depression in elderly individuals with
chronic kidney disease (CKD) is estimated at 15 – 30%
[6]. Older adults have age-related changes in drug* Correspondence: amit.garg@lhsc.on.ca
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unless otherwise stated.metabolism that can increase their risk of adverse drug ef-
fects, a finding particularly true for many anti-depressants
[7-9]. Up to 30% of these older adults also have CKD,
which can cause drug accumulation through reduced
elimination, further increasing the risk of adverse events
[10,11]. A number of pharmacokinetic studies have dem-
onstrated that the serum half lives of three common anti-
depressants (paroxetine, mirtazapine or venlafaxine) are
significantly prolonged in individuals with CKD [6,12-14].
Additionally, several case reports link the use of these
three anti-depressants to delirium, a state of acute. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[15-18]. Thus, in CKD, use of lower doses of these three
anti-depressants is recommended in drug prescribing ref-
erences (recommendations summarized in Table 1). Using
information available in large population-based healthcare
administrative databases, we conducted this study in older
adults to determine if ignoring the recommendation and
initiating a higher vs. lower dose of three study anti-
depressants (paroxetine, mirtazapine or venlafaxine) asso-
ciates with a higher risk of adverse events. The two
outcomes assessed in our data sources were 30-day risk of
delirium (assessed through a proxy of hospitalization with
an urgent head computed tomography (CT) scan) and
mortality. We also examined if the presence of CKD
modified the association between anti-depressant dose
(higher v. lower) and outcome.
Methods
Setting and study design
Residents of the province of Ontario, Canada have uni-
versal access to hospital care and physician services.
Those 65 years of age or older, representing approxi-
mately 2 million individuals in 2012, also have universal
prescription coverage [25]. All health care encounters in
Ontario are recorded in linked, de-identified databases
at the Institute for Clinical Evaluative Sciences (ICES).
We conducted a retrospective, population-based cohort
study using six of these healthcare databases. We con-
ducted this study according to a pre-specified protocol that
was approved by the research ethics board at Sunnybrook
Health Sciences Centre (Toronto, Canada). The reporting
of this study follows guidelines for observational studies
(detailed in Additional file 1: Figure S1) [26].
Data sources
We ascertained baseline characteristics, drug use and dose,







Paroxetine > 20 ≤ 20 • 20 – 50 mg/day
• Reduce by 50% with
CrCl < 30 ml/min
Mirtazapine > 20 ≤ 20 • 15 – 45 mg/day
• Use with caution with
CrCl < 40 ml/min
Venlafaxine > 37.5 ≤ 37.5 • 75 – 225 mg/day
• Reduce by 25 – 50% with
CrCl 10 – 70 ml/min
*As defined in this study.
Abbreviations: CrCl Creatinine clearance, eGFR estimated glomerular filtration rate.Demographic and vital status information on all Ontario
residents who have ever been issued a health card is re-
corded in the Ontario Registered Persons Database (RPDB).
Detailed diagnostic and procedural information on all hos-
pital admissions and emergency room visits is recorded in
the Canadian Institute for Health Information Discharge
Abstract Database (CIHI-DAD) and the National Ambula-
tory Care Reporting System (NACRS), respectively. Health
claims for inpatient and outpatient physician services are
recorded in the Ontario Health Insurance Plan database
(OHIP). Outpatient prescription drug information includ-
ing the dispensing date, quantity of pills, dose, and number
of days supplied is accurately recorded in the Ontario Drug
Benefit Program database (ODB), with an error rate less
than 1% [27]. Lastly, the ICES Physician Database (IPDB)
contains information on all physicians in Ontario such as
sub-specialty, education, location and demographics.
Among a subpopulation of patients with prescriptions
filled in Southwestern Ontario, we also obtained baseline
serum creatinine values from two linked laboratory data-
sets: Gamma-Dynacare, a large outpatient provincial la-
boratory provider and Cerner® (Kansas City, Missouri,
USA), an electronic medical record database containing
inpatient, outpatient, and emergency department labora-
tory values for 12 hospitals in Southwestern Ontario
[28]. The most recent serum creatinine was obtained in
the year prior to the study anti-depressant prescription
(median 94 days prior to the prescription). These data
sources have been used previously to study drug safety
[29-31]. With the exception of anti-depressant prescriber
specialty and income quintile (missing in 13.5% and
0.3% of patients, respectively), the databases were
complete for all variables used in this study.
Patients
We established a cohort of all older adults in Ontario




• 20 – 50 mg/day • 20 – 50 mg/day
• Initiate at 10 mg/day with
CrCl < 40 ml/min
• Initiate at 10 mg/day with
eGFR < 60 ml/min
• 15 – 45 mg/day • 15 – 45 mg/day
• Use with caution • Use with caution
• Initiate at 15 mg/day with
eGFR < 30 ml/min
• 75 – 225 mg/day • 75 – 225 mg/day
• Reduce by 25 – 50% with
GFR 10–70 ml/min
• Reduce to 37.5 mg/day with
eGFR < 30 ml/min
• Initiate at 37.5 mg/day
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any type of study or non-study anti-depressant in the
prior six months) between April 1st, 2002 and December
31st 2011 (n = 169,435). The three study anti-depressants
were paroxetine, mirtazapine, and venlafaxine. Patients
with multiple eligible prescriptions could only enter the
cohort once, and the date of anti-depressant initiation
served as the patient’s index date (cohort entry date;
start of follow-up). We assessed baseline demographic
characteristics, co-morbid conditions (5 years prior to
index date) and concurrent drug therapy (180 days prior
to index date) among all individuals. We excluded the
following anti-depressant users from the analysis: those
in the first year of eligibility for prescription drug cover-
age (age 65 years) to avoid incomplete medication records
(n = 12,588); those who were discharged from hospital in
the two days before their index date to ensure that pre-
scriptions were new outpatient anti-depressant prescrip-
tions (as in Ontario, patients continuing an antidepressant
treatment initiated in hospital would have their oral out-
patient antidepressant prescription dispensed on the same
day or the day after hospital discharge) (n = 3,833); those
living in long-term care facilities because some residents
chronically experience bouts of confusion (n = 30,360);
those with end-stage renal disease since treatments such
as dialysis alter anti-depressant pharmacokinetics unpre-
dictably [14] (n = 1,522); and those who received more
than one type of anti-depressant on their index date to
allow comparison of mutually exclusive exposure groups
(n = 3,321). A total of 117,811 patients were included in
the final analysis.
We identified individuals with moderate CKD using an
algorithm of diagnosis codes validated in our region for
older adults [32]. The algorithm identifies a group of pa-
tients with a low GFR by the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) formula. It identi-
fied patients with a median estimated glomerular filtration
rate (eGFR) of 38 mL/min per 1.73 m2 (interquartile range
27 to 52), whereas its absence identified patients with a
median eGFR of 69 mL/min per 1.73 m2 (interquartile
range 56 to 82).
Anti-depressant dose
To align with recommendations in drug prescribing ref-
erences, a higher dose of anti-depressant was defined as
> 20 mg/day of paroxetine, > 20 mg/day of mirtazapine,
or > 37.5 mg/day of venlafaxine (Table 1). A lower dose
of anti-depressant was defined as ≤ 20 mg/ day of parox-
etine, ≤ 20 mg/day of mirtazapine, or ≤ 37.5 mg/day of
venlafaxine (Table 1).
Outcomes
As most reported anti-depressant related delirium oc-
curs within the first few weeks of drug initiation, wefollowed all individuals for 30 days after first anti-
depressant use for two pre-specified outcomes [33]. Our
primary outcome was hospitalization with evidence of
an urgent head CT scan. We used this as a proxy for the
presence of acute central nervous system disturbance (i.e.
delirium), as many patients in Ontario undergo such diag-
nostic imaging when presenting to hospital with acute
confusion. Unlike diagnostic codes for acute delirium, the
receipt of a head CT scan is well coded in our data sources
because they are associated with physician reimbursement
[34]. To focus on urgent imaging conducted for acute rea-
sons at the time of hospital admission, we only considered
head CT scans performed in the first five days of a hospital
admission, or in the emergency department assessment
preceding the hospital admission. We expected urgent
head CT scans conducted for reasons unrelated to anti-
depressant dosing (e.g. stroke, headache) to occur at a
similar frequency in higher and lower dose groups, not
impacting estimates of difference in risk between the two
groups. Our secondary outcome was all-cause mortality
which is well coded in our data sources [35].
Statistical analysis
We compared baseline characteristics between those
prescribed higher vs. lower daily doses of study anti-
depressants using standardized differences. This metric
describes differences between group means relative to
the pooled standard deviation and indicates a meaning-
ful difference if greater than 10% [36]. We used multi-
variable logistic regression analyses (PROC LOGISTIC;
SAS Institute, Cary, North Carolina) to estimate adjusted
odds ratios and 95% confidence intervals. We adjusted
for 15 potential confounders: antidepressant type, age,
sex, year of cohort entry, modified Charlson score (a co-
morbidity index), and concurrent medication use (anti-
convulsants, gabapentin, antipsychotics, barbiturates,
benzodiazepines, histamine2-receptor antagonists, dopa-
mine agonists, muscle relaxants, opioids and overactive
bladder medications). Outcomes are expressed with pa-
tients receiving a lower dose of anti-depressant as the
referent group. We then tested for statistical interactions
to determine whether the association between anti-
depressant drug dose (higher vs. lower) and outcome
was modified by the presence of moderate CKD. All
odds ratios were interpreted as relative risks (appropriate
given the low incidences observed). We conducted all
statistical analyses using SAS, version 9.3.
Results
The study included 117,811 eligible older adults in rou-
tine outpatient care who were dispensed a new oral
study anti-depressant (patient selection diagram pre-
sented in Additional file 1: Figure S1). A total of 36,651
patients (31%) were initiated on a higher anti-depressant
Table 2 Baseline characteristics by anti-depressant dose
Higher dose Lower dose Standardized
differenceN = 36,651 N = 81,160
Anti-depressant type, n (%)
Paroxetine 4,216 (11.5) 41,889 (51.6) 0.96
Mirtazapine 9,531 (26.0) 15,101 (18.6) 0.18
Venlafaxine 22,904 (62.5) 24,170 (29.8) 0.69
Demographics
Age, years, mean (SD) 73.7 (6.8) 75.6 (5.8) 0.29
Women, n (%) 22,472 (61.3) 54,631 (67.3) 0.13
Year of cohort entry, n (%)
2002-2005 16,434 (44.8) 4,2770 (52.7) 0.16
2006-2009 14,661 (40.0) 2,7984 (34.5) 0.11
2010-2011 5,556 (15.2) 10,406 (12.8) 0.07
Income quintile, n (%)
First (lowest) 7,663 (20.9) 16,725 (20.6) 0.01
Second 7,552 (20.6) 17,627 (21.7) 0.03
Third (middle) 7,034 (19.20 16,003 (19.7) 0.01
Fourth 7,118 (19.4) 15,226 (18.8) 0.02
Fifth (highest) 7,142 (19.5) 15,327 (18.9) 0.02
Missing 142 (0.4) 252 (0.3) 0.01
Rural Location, n (%) 5,386 (14.7) 10,943 (13.5) 0.03
Modified Charlson scoreŦ, n (%)
0 or no hospitalization 25,360 (69.2) 56,063 (69.0) 0.00
1 4,263 (11.6) 9,548 (11.7) 0.00
2 3,514 (9.6) 7,571 (9.3) 0.01
≥3 3,514 (9.6) 8,005 (9.9) 0.01
Co-morbidities£, n (%)
Chronic liver disease 1,348 (3.7) 2,970 (3.7) 0.00
Chronic kidney disease* 1,609 (4.4) 3,772 (4.7) 0.01
Chronic obstructive pulmonary disease 1,849 (5.0) 4,389 (5.4) 0.02
Coronary artery disease¶ 12,951 (35.3) 31,350 (38.6) 0.07
Heart failure 4,133 (11.3) 10,715 (13.2) 0.06
Stroke/Transient ischemic attack 1,148 (3.1) 2,625 (3.2) 0.01
Diabetes mellitus (on medication)+ 5,878 (16.0) 12,203 (15.0) 0.03
Medication¥, n (%)
Anticonvulsants 3,728 (10.2) 6,574 (8.1) 0.07
Gabapentin 363 (1.0) 525 (0.7) 0.04
Antipsychotics 2,499 (6.8) 3,752 (4.6) 0.09
Barbiturates 89 (0.2) 163 (0.2) 0.01
Benzodiazepines 15,736 (42.9) 35,681 (44.0) 0.02
Histamine2-receptor antagonists 3,417 (9.3) 9,764 (12.0) 0.09
Dopamine agonists 298 (0.8) 517 (0.6) 0.02
Muscle relaxants 311 (0.9) 564 (0.7) 0.02
Opioids 10,408 (28.4) 21,632 (26.7) 0.04
Overactive bladder medications 1,424 (3.9) 2,992 (3.7) 0.01
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Table 2 Baseline characteristics by anti-depressant dose (Continued)
Prescribing physician, n (%)
General practitioner 27,884 (76.1) 62,622 (77.2) 0.03
Internist 251 (0.7) 669 (0.8) 0.02
Neurologist 179 (0.5) 408 (0.5) 0.00
Other 3,514 (9.6) 6,354 (7.8) 0.06
Missing 4,823 (13.2) 11,107 (13.7) 0.02
£Co-morbidities were assessed in the five years prior to the index date using International Classification of Diseases 9th revision (ICD-9) and 10th revision (ICD-10) codes.
ŦAssessed with an algorithm using diagnosis codes from hospitalizations in the five years prior; patients with no hospitalizations during this period were given a
value of zero.
*Identified individuals with CKD using an algorithm of diagnosis codes validated in our region for older adults [32].
The algorithm identified patients with a median estimated glomerular filtration rate (eGFR) of 38 mL/min per 1.73 m2 (interquartile range 27 to 52), whereas its
absence identified patients with a median eGFR of 69 mL/min per 1.73 m2 (interquartile range 56 to 82).
¶Coronary artery disease includes receipt of coronary artery bypass graft surgery, percutaneous coronary intervention and diagnoses of angina.
¥Medication use was assessed in the 180 days prior to the index date.
+Diabetic medications include oral hypoglycemics and insulin.
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anti-depressant dose. Most prescriptions were written by
a primary care physician (76.8%). There was no signifi-
cant difference in 20 of the 25 measured baseline char-
acteristics between the higher and lower anti-depressant
dose groups (Table 2). However, compared to those in
the lower dose group, patients in the higher dose group
were more likely to be prescribed mirtazapine and venla-
faxine (26.0% vs. 18.6%, and 62.5% vs. 29.8%, respect-
ively), were more likely to be younger (mean 73.7 years
vs. 75.6 years), were more likely to enter the cohort be-
tween the years 2006 to 2009 (40.0% vs. 34.5%), were less
likely to enter the cohort between the years 2002 to
2005 (44.8% vs. 52.7%) and were less likely to be women
(61.3% vs. 67.3%).
30-day hospitalization with urgent head Computed
Tomography (CT) scan
Initiation of a higher vs. lower anti-depressant dose was
associated with a lower risk of hospitalization with head
CT scan (Table 3; 400/36,651 [1.09%] vs. 1,033/81,160
[1.27%], unadjusted relative risk 0.86 [95% CI 0.76 to
0.96]). After adjusting for 15 potential confounders the
association was no longer significant (Table 3; adjusted
relative risk 0.90 [95% CI 0.80 to 1.02]). The associationTable 3 Association between anti-depressant dose and 30-da
Number of events, n (%)
Higher dose£ Lower do
N = 36,651 N = 81,16
Hospital admission with head CT scan 400 (1.09) 1,033 (1.2
All-cause mortality 278 (0.76) 791 (0.97)
£Higher dose of anti-depressant defined as > 20 mg/day of paroxetine, > 20 mg/day
¶Lower dose of anti-depressant defined as ≤ 20 mg/ day of paroxetine, ≤ 20 mg/da
¥Adjusted for 15 covariates (see Methods).
(…) Absolute risk difference was not calculated as adjusted relative risk was not sta
Patients prescribed the lower anti-depressant dose served as the referent group.
Abbreviations: CI confidence interval, CT computed tomography.was not appreciably different in patients with and with-
out moderate CKD (when the presence of this condition
was assessed with diagnosis codes; Figure 1; interaction
P value = 0.16). The association was also not appreciably
different in patients with and without moderate CKD
when examined separately by each of the three anti-
depressant drugs (recognizing stratifying the results in
this way resulted in smaller sample sizes and wider con-
fidence intervals; Figure 2).
30-day all-cause mortality
Initiation of a higher vs. lower anti-depressant dose was as-
sociated with a lower risk of 30-day all-cause mortality
(Table 3; 278/36,651 [0.76%] vs. 791/81,160 [0.97%], abso-
lute risk reduction 0.22% [95% CI 0.10% to 0.33%], un-
adjusted relative risk 0.78 [95% CI 0.68 to 0.89]). Adjusting
for 15 potential confounders had no appreciable impact on
this observed association (adjusted relative risk 0.82 [95%
CI 0.71 to 0.95; Table 3). The association was not appre-
ciably different in patients with and without moderate CKD
(when the presence of this condition was assessed with
diagnosis codes; Figure 1; interaction P value = 0.96). The
association was also not appreciably different in patients
with and without moderate CKD when examined separ-
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Figure 1 Association between anti-depressant dose and adverse events in patients with and without Chronic Kidney Disease (CKD;
where CKD was defined by diagnosis codes). There was no difference in association between anti-depressant dose and adverse events in
patients with and without CKD (interaction p-value 0.163 and 0.962, respectively for each outcome). Estimates of risks for patients without CKD
(n = 112,430) were more precise than for patients with CKD (n = 5,381). Adjusted for 15 covariates: antidepressant type, age, sex, year of cohort
entry, modified Charlson score (a co-morbidity index), and concurrent medication use (anticonvulsants, gabapentin, antipsychotics, barbiturates,
benzodiazepines, histamine2-receptor antagonists, dopamine agonists, muscle relaxants, opioids and overactive bladder medications). Abbreviations:
CI, confidence interval; CT, computed tomography.












































































0.67 (0.53 to 0.85)
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0.81 (0.54 to 1.22)
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1.32 (0.40 to 4.43)
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0.61 (0.41 to 0.90)
1.21 (0.68 to 2.16)
0.86 (0.45 to 1.04)








Figure 2 Association between anti-depressant dose and adverse events in patients with and without Chronic Kidney Disease (CKD) stratified
by the type of anti-depressant. With a smaller number of patients and events, estimates of risks for patients with CKD were less precise than for patients
without CKD. Stratified models by antidepressant type adjusted for 14 covariates: age, sex, year of cohort entry, modified Charlson score (a co-morbidity
index), and concurrent medication use (anticonvulsants, gabapentin, antipsychotics, barbiturates, benzodiazepines, histamine2-receptor antagonists,
dopamine agonists, muscle relaxants, opioids and overactive bladder medications). Abbreviations: CI, confidence interval; CT, computed tomography.
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We repeated our analysis in a subpopulation of older
adults with baseline serum creatinine values (n = 24,641)
comparing a higher vs. lower anti-depressant dose and
each of our two outcomes. In this analysis the clinically
important threshold used to define moderate CKD was
an eGFR < 45 mL/min per 1.73 m2 (as higher eGFR
thresholds (45 to 60 mL/min per 1.73 m2) may not iden-
tify substantial CKD in the elderly, and choosing a lower
eGFR threshold (<30 mL/min per 1.73 m2) meant less
patients (n = 587 for this analysis)). Results are presented
in Figure 3. Point estimates of the relative risk of a
higher vs. lower anti-depressant dose and outcomes of
head CT and all-cause mortality were all below a value
of 1 in patients with and without a baseline eGFR value
< 45 mL/min per 1.73 m2. The association was not ap-
preciably different in those with and without moderate
CKD (Figure 3; interaction P value = 0.73 and 0.19 for
each outcome, respectively).
In the primary cohort we considered the outcome of
hospitalization using diagnostic codes for delirium (rec-
ognizing the coding for this outcome is insensitive and
underestimates events but was expected not to operate
differently in the two anti-depressant dose groups). Initi-
ation of a higher vs. lower anti-depressant dose was not
associated with a difference in risk of hospitalization
with delirium (43/36,651 [0.16%] vs. 126/81,160 [0.12%],Figure 3 Association between anti-depressant dose and adverse even
where the presence of CKD was defined by an estimated glomerular
of the relative risk with a higher vs. lower anti-depressant dose and outcom
the association not appreciably different in those with and without CKD. A
entry, modified Charlson score (a co-morbidity index), and concurrent med
benzodiazepines, histamine2-receptor antagonists, dopamine agonists, muscl
CI, confidence interval; CT, computed tomography.unadjusted relative risk 0.76 [95% CI 0.53 to 1.07]). The
association was not different in patients with and with-
out moderate CKD (interaction P value = 0.75).
Discussion
We report the 30-day risk of two major adverse events
as assessed in large healthcare administrative databases
in older adults who initiated a higher vs. lower dose of
one of three common anti-depressants used in routine
outpatient care. Contrary to our expectation, compared
to a lower dose, initiation of a higher dose of anti-
depressant was associated with a lower 30-day risk of
all-cause mortality. This association appeared similar in
patients with and without moderate CKD, although esti-
mates in patients with CKD were less precise. There was
no association between the anti-depressant dose and the
risk of hospitalization with urgent neuroimaging, an ex-
treme outcome in the spectrum of delirium.
It is well established that older individuals are more
prone to adverse drug reactions [8,9,33]. We hypothe-
sized that the presence of moderate CKD would make
older adults particularly vulnerable to toxicity from
higher doses of three study anti-depressants that have
been shown to accumulate in CKD (paroxetine, mirtaza-
pine, venlafaxine). The data supporting dose reductions
of these anti-depressants comes from pharmacokinetic
studies and case studies [6,12]. To our knowledge, ourts in patients with and without Chronic Kidney Disease (CKD)
filtration rate (eGFR) < 45 mL/min per 1.73 m2. All point estimates
es were below a value of 1 in patients with and without CKD, with
djusted for 15 covariates: antidepressant type, age, sex, year of cohort
ication use (anticonvulsants, gabapentin, antipsychotics, barbiturates,
e relaxants, opioids and overactive bladder medications). Abbreviations:
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failing to dose adjust anti-depressants in the setting of
moderate CKD at the population level. There is a need to
determine if drug dosing decisions based on pharmacoki-
netic data influence real practice outcomes. The lower risk
of death we observed with higher doses of anti-depressant
was contrary to our hypothesis. It is possible the associ-
ation relates to unmeasured confounding between the two
dosing groups. It is also possible that higher vs. lower
doses of anti-depressants are more efficacious in treating
depression and improve survival. Inadequately treated de-
pression can increase mortality risk through nonadher-
ence to medications and health care appointments, poor
nutrition, lack of social support, increased inflammation
and compromised immunity [37-40]. Examining the
causes of death such as suicide or withdrawal of care in
this context would be useful in future studies, as such in-
formation was not reliable in our data sources.
With respect to patient safety, if concerns remain
about the use of certain anti-depressants in patients with
moderate CKD, a reasonable alternative is to prescribe
an anti-depressant such as fluoxetine where the pharma-
cokinetics are not altered by the presence of CKD. Ob-
servational data also suggests that this anti-depressant is
well tolerated by patients with CKD [14].
Our study has several strengths. The use of Ontario’s
broadly inclusive healthcare databases provided us with
a large representative sample. The data was complete,
drug dose and outcomes were accurately recorded, and
patient loss to follow-up was minimal (emigration in our
region is less than 1% per year) [41].
Our study has several limitations. The similarity of
measured patient baseline characteristics in our two
anti-depressant dose groups helped reduced concerns
about the influence of confounding. The concern over
residual confounding was also reduced by the lack of
substantial change in the observed association after ad-
justment for multiple potential confounders. However,
as mentioned, as in any observational study the possibil-
ity of unmeasured confounding can never be completely
eliminated. We knew the anti-depressant was dispensed
by a pharmacy but had no information on compliance.
Future studies should include more patients with very
low levels of eGFR (i.e. < 30 mL/min per 1.73 m2), and
should also collect body weight so that eGFR can also be
expressed in mL/min. Our primary outcome was assessed
retrospectively using existing healthcare database records
and relied on urgent neuroimaging as a proxy for the diag-
nosis of delirium, which is an insensitive method to iden-
tify important changes in cognition. Rather, if resources
allow for it, a well-designed prospective study with inde-
pendent outcome adjudication would more precisely cap-
ture benefits and risks associated with initiating a higher
vs. lower anti-depressant dose.Conclusion
In this study which used large healthcare administrative
databases, contrary to our hypothesis we failed to ob-
serve an association between initiation of a study anti-
depressant at a higher dose and a higher risk of two ad-
verse outcomes in older adults with moderate CKD.
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